Related Experiment Video
Updated: Jul 15, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Recombinant-activated coagulation factor VIIa (NovoSeven): current development
1Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Denmark. rwes@novonordisk.com
Abstract:
Recombinant activated coagulation factor VII (rFVIIa) was developed initially for treatment of patients with hemophilia and neutralizing antibodies ("inhibitors") to coagulation factors VIII or IX. Owing to the unique and selective mechanism of action of rFVIIa and encouraged by clinical experience with other circumstances of inadequate hemostasis, a broad development program has been pursued to test potential efficacy and evaluate safety of this biologic for indications other than hemophilia. This review summarizes the current development of rFVIIa, focusing on results of prospective, randomized clinical trials.
Related Concept Videos
Coagulation
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care

